COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations
作者机构：Department of Internal MedicineUniversity of NaplesNaples 80100Italy FarmaciaFarmacia MorroneCasoria 80022Italy Department of Internal MedicineCardiovascular and Immunologic SciencesFedericoⅡUniversity of NaplesNapoli 80100Italy
出 版 物：《World Journal of Meta-Analysis》 (世界荟萃分析杂志)
年 卷 期：2020年第8卷第3期
页 面：173-177页
学科分类：1007[医学-药学(可授医学、理学学位)] 10[医学]
主 题：COVID-19 Evidence based medicine Hydroxycloroquine Azithromycine Indomethacine Doxycycline
摘 要：The world pandemic due to coronavirus disease 2019,known as COVID-19,embodies a high rate of disease transmission that causes a critical hospitalization *** of May 15,2020,the disease has been the cause of more than 4 million infections and more than 280000 deaths all over the *** the beginning,we underestimated the disease;now,we have sufficient information and it is clear that it is not just a respiratory *** fact,if a prompt treatment is not initiated,the disease may evolve towards an abnormal immune response and cytokine storm with an important thrombophilic ***,we think that while waiting for certainties to be established by evidence-based medicine,it is not ethical to not try off-label therapies for some of the well-known drugs,as they could have some efficacy based on their mechanisms of action.
维普期刊数据库